Tech Company Financing Transactions
Vyriad Funding Round
Vyriad, operating out of Rochester, secured $25 million from private investors.
Transaction Overview
Company Name
Announced On
1/2/2026
Transaction Type
Venture Equity
Amount
$25,000,000
Round
Series B
Investors
private investors (Lead Investor) (Harry Stine)
Proceeds Purpose
This additional funding supports the imminent first-in-human testing of VV169, Vyriad's in vivo CAR-T candidate, in patients with relapsed or treatment-refractory multiple myeloma.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2900 37th St. NW Building 110
Rochester, MN 55901
USA
Rochester, MN 55901
USA
Phone
Website
Email Address
Overview
Vyriad is a clinical-stage company developing proprietary oncolytic virus therapies for the treatment of cancers with significant unmet needs. The potentially life-changing oncolytic viral technologies of Vyriad are the result of decades of research by dedicated researchers and clinicians at Mayo Clinic and the University of Miami.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Stephen Russell
Chief Financial Officer
Jim Hannon
Chief Medical Officer
Alice Bexon
Chief Technical Officer
Kah-Whye Peng
Browse more venture capital transactions:
Prev: 1/2/2026: Zero Homes venture capital transaction
Next: 1/3/2026: Biobeat Technologies venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We record every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs